Active Ingredient: Vorasidenib
Voranigo as monotherapy is indicated for the treatment of predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation in adult and adolescent patients aged 12 years and older and weighing at least 40 kg who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.
For this indication, competent medicine agencies globally authorize below treatments:
For:
In case that patient weight is ≥ 40 kg
Oral, 40 milligrams vorasidenib, once daily.
The recommended dose of vorasidenib in adults and adolescents 12 years of age and older is 40 mg once daily for patients weighing at least 40 kg. No dose recommendation can be made in patients weighing less than 40 kg because of the lack of clinical data in this population.
Treatment should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient.
If a dose is missed or not taken at the usual time, it should be taken as soon as possible within 6 hours after the missed dose. The next dose should be taken at the regularly scheduled time.
If a dose is missed by more than 6 hours, it should be skipped and the next dose should be taken at the regularly scheduled time.
If a dose is vomited, replacement dose should not be taken. The dose should be taken as usual the following day.
Complete blood counts and blood chemistries, including liver enzymes, should be assessed prior to starting treatment, every 2 weeks during the first 2 months and then once monthly for the first 2 years of treatment, and as clinically indicated thereafter. Certain patients may require more frequent and ongoing monitoring.
Dose interruption or dose reduction may be required based on individual safety and tolerability. The recommended dose reduction levels are provided in the following table.
Recommended dose reduction levels:
| Dose level | Dose and schedule |
|---|---|
| Starting dose | 40 mg once daily |
| First dose reduction | 20 mg once daily |
| Second dose reduction | 10 mg once daily |
Vorasidenib should be taken once daily at about the same time each day. Patients should not eat food at least 2 hours before and 1 hour after taking vorasidenib.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.